Pharma Journalist -

The U.S. Food and Drug Administration (FDA) has accepted Bayer's Biologics License Application (BLA) filing for BAY94-9027, an extended half-life site-specifically PEGylated recombinant…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the pivotal phase 3 placebo-controlled ENLIVEN (NCT02371369) study of pexidartinib met its primary…
Read More...

Novartis announced that the company has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Kymriah™ (tisagenlecleucel)…
Read More...

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH)…
Read More...

Charles River Laboratories International, Inc. announced its partnership with InSphero AG, a leading supplier of 3D solutions for in vitro drug discovery and development. Through…
Read More...

Zydus Cadila has received the final approval from the USFDA to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base). The drug is indicated to treat…
Read More...

Lannett Company, Inc. announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S. related to…
Read More...

Xynomic Pharma announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim, a…
Read More...

SMi Reports: SMi’s 2nd annual Drug Discovery conference,taking place in London on 21st and 22nd March 2018, will discuss the role of artificial intelligence in drug discovery ‘The…
Read More...